Browsing by Author "Ferrés Garrido, Marcela Viviana"

Now showing 1 - 20 of 32
  • Thumbnail Image
    Item
    A rapid method for infectivity titration of Andes hantavirus using flow cytometry
    (2013) Barriga, Gonzalo P.; Martínez Valdebenito, Constanza; Galeno, Héctor; Ferrés Garrido, Marcela Viviana; Lozach, Pierre Yves; Tischler, Nicole D.
  • Thumbnail Image
    Item
    Ampliación del rango de distribución de Oligoryzomys longicaudatus (Rodentia, Sigmodontinae) en la Patagonia de Chile y primer registro de Hantavirus en la región
    (2009) Belmar Lucero, Sebastián Antoni; Godoy Moraga, Paula Roxana.; Ferrés Garrido, Marcela Viviana; Palma Vásquez, Ramón Eduardo
  • Thumbnail Image
    Item
    Andes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile
    (2010) Torres Pérez, Fernando; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Caracterización clínica y epidemiológica de infección asociada a atención en salud por virus influenza en pacientes críticos
    (2019) Gutiérrez, Valentina; Cerda, Jaime; Le Corre Pérez, Monique Nicole; Medina, Rafael; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Detección precoz de infección por citomegalovirus en pacientes sometidos a trasplante alogéneico de precursores hematopoyéticos por reacción de polimerasa en cadena cuantitativa en tiempo real
    (2014) Ceballos, María Elena; Vizcaya Altamirano, María Cecilia; Pavez, D.; Cerda, Jaime; Martínez Valdebenito, C.; Montecinos, L.; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
    (2021) Balcells Marty, Maria Elvira; Rojas Orellana, Luis Esteban; Martínez Valdebenito, Constanza Pamela; Ceballos Valdivielso, María Elena Andrea; Ferrés Garrido, Marcela Viviana; Chang Rathkamp, Mayling Raquel; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Huete Garín, Isidro Álvaro; Castro López, Ricardo Adolfo; Sarmiento Maldonado, Mauricio; Villarroel Del Pino, Luis Antonio; Pizarro Ibáñez, Alejandra Valentina; Ross Pérez, Patricio Daniel; Santander Toro, Jaime Andrés; Lara Hernández, Bárbara Alejandra; Ferrada Koch, Marcela Patricia; Vargas Salas, Sergio Sebastián; Beltrán Pávez, Carolina; Soto Rifo, Ricardo; Valiente Echeverria, Fernando Andrés; Caglevic, Christian; Mahave, Mauricio; Selman Bravo, Carolina Antoniett; Gazitúa, Raimundo; Briones, José Luis; Villarroel Espíndola, Franz; Balmaceda Araque, Carlos Felipe; Espinoza Sepúlveda, Manuel Antonio; Pereira Garces, Jaime; Nervi Nattero, Bruno; Le Corre Perez, Monique Nicole
    Background: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression.", "Methods and findings", "The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion.", "Conclusions", "In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
  • Thumbnail Image
    Item
    Ecology, Genetic Diversity, and Phylogeographic Structure of Andes Virus in Humans and Rodents in Chile
    (2009) Medina, Rafael; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Estrategias para reducir infecciones, uso de antimicrobianos y sus efectos en una unidad de neonatología
    (2017) Urzúa Baquedano, María Soledad; Ferrés Garrido, Marcela Viviana; García Cañete, Patricia; Sánchez, Amparo; Luco Illanes, Matías Fernando
  • Thumbnail Image
    Item
    Evaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples
    (2018) González Carreño, Liliana Andrea; Vazquez, Yaneisi; Mora, Jorge E.; Palavecino, Christian E.; Bertrand N., Pablo; Ferrés Garrido, Marcela Viviana; Contreras, Ana María; Beckhaus, Andrea A.; Riedel, Claudia; Bueno Ramírez, Susan
  • Thumbnail Image
    Item
    Exactitud y utilidad diagnóstica de la IgM en infecciones por Bartonella henselae
    (2013) Abarca Villaseca, Katia; Winter, Matías; Marsac, Delphine; Palma, Carlos; Contreras, Ana M.; Ferrés Garrido, Marcela Viviana
  • Thumbnail Image
    Item
    Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration
    (2016) Bugedo Tarraza, Guillermo; Florez, Jorge; Ferrés Garrido, Marcela Viviana; Roessler Barrón, Eric; Bruhn, Alejandro
  • Thumbnail Image
    Item
    Hantavirus: descripción de dos décadas de endemia y su letalidad
    (2018) Reyes Zaldivar, Felipe Tomás; Ferrés Garrido, Marcela Viviana
    Introducción: la infección por hantavirus es una zoonosis endémica en Chile. En dos décadas la letalidad ha descendido a una cifra estable de alrededor de un 30%, pese a importantes esfuerzos por disminuirla. Objetivos: describir los eventos que ocurren antes de la hospitalización y analizar la relación entre estas variables y la letalidad, con el objetivo de identificar momentos de intervención para mejorar la sobrevida de los pacientes. Material y Métodos: se analizaron retrospectivamente todos los casos notificados a través del Boletín Notificación Enfermedades de Declaración Obligatoria (ENO), la Encuesta Epidemiológica de Investigación Ambiental de los casos de Hantavirus del Ministerio de Salud de Chile. Resultados: existieron diferencias significativas en la letalidad por HV determinada por zona geográfica, tipo de trabajo y hospital donde se atendió primariamente el caso. Conclusiones: Hantavirus, por su rápida evolución hacia una condición catastrófica debe tenerse siempre presente en el diagnóstico diferencial y proceder en consecuencia para tener un diagnóstico precoz y acceso a un centro hospitalario con experiencia en manejo de esta patología.
  • Thumbnail Image
    Item
    Hantaviruses and cardiopulmonary syndrome in South America
    (2014) Figueiredo, L.; Souza, W.; Ferrés Garrido, Marcela Viviana; Enria, D.
  • Thumbnail Image
    Item
    High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile : a double-blind, randomized controlled clinical trial
    (2013) Vial, Pablo A.; Valdivieso, Francisca; Ferrés Garrido, Marcela Viviana; Riquelme, Raúl; Rioseco, M. Luisa; Calvo, Mario; Castillo, Constanza; Díaz, Ricardo; Scholz, Luis; Cuiza, Analia
  • Thumbnail Image
    Item
    HIV-1 tropism : a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients
    (2013) Ferrés Garrido, Marcela Viviana; Montecinos, Luisa; Tello, Mario; Tordecilla, Rocío; Rodríguez, Consuelo; Pérez, Carlos; Beltrán, Carlos; Guzmán Meléndez, María Antonieta; Afani Saud, Alejandro
  • Thumbnail Image
    Item
    Identification of biomarkers for disease severity in nasopharyngeal secretions of infants with upper or lower respiratory tract viral infections
    Bertrand N., Pablo; Vazquez, Yaneisi; Beckhaus, Andrea A.; González Carreño, Liliana Andrea; Contreras Sepúlveda, Ana María; Ferrés Garrido, Marcela Viviana; Padilla Pérez, Oslando; Riedel, Claudia A.; Kalergis Parra, Alexis Mikes; Bueno, Susan M.
    Lower respiratory tract infections (LRTIs) produced by viruses are the most frequent cause of morbidity and mortality in children younger than 5 years of age. The immune response triggered by viral infection can induce a strong inflammation in the airways and cytokines could be considered as biomarkers for disease severity as these molecules modulate the inflammatory response that defines the outcome of patients. Aiming to predict the severity of disease during respiratory tract infections, we conducted a 1-year follow-up observational study in infants who presented upper or lower respiratory tract infections caused by seasonal respiratory viruses. At the time of enrollment, nasopharyngeal swabs (NPS) were obtained from infants to measure mRNA expression and protein levels of IL-3, IL-8, IL-33, and thymic stromal lymphopoietin. While all cytokines significantly increased their protein levels in infants with upper and lower respiratory tract infections as compared to control infants, IL-33 and IL-8 showed a significant increase in respiratory syncytial virus (RSV)-infected patients with LRTI as compared to patients with upper respiratory tract infection. We also found higher viral loads of RSV-positive samples with a greater IL-8 response at the beginning of the symptoms. Data obtained in this study suggest that both IL-8 and IL-33 could be used as biomarkers for clinical severity for infants suffering from LRTIs caused by the RSV.
  • Thumbnail Image
    Item
    Infección del sitio quirúrgico en niños sometidos a cirugía cardíaca con cierre esternal diferido. Estudio de casos y controles
    (2016) Retamal, Javiera; Becker Rencoret, Pedro Antonio; González Foretic, Rodrigo Vicente; Ferrés Garrido, Marcela Viviana; Cerda, Jaime; Riquelme, María I.; Pérez, R.; Clavería Rodríguez, Cristian
  • Thumbnail Image
    Item
    Infecciones asociadas a la atención en salud (IAAS) en pacientes pediátricos post-operados de cardiopatías congénitas
    (2014) Barriga, J.; Cerda, Jaime; Abarca Villaseca, Katia; Ferrés Garrido, Marcela Viviana; Fajuri, P.; Riquelme, M.; Carrillo, D.; Clavería Rodríguez, Cristian
  • Thumbnail Image
    Item
    Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability
    (2011) Marsac, Delphine; García, Stephanie; Pino, Karla; Ferrés Garrido, Marcela Viviana; López Lastra, Marcelo Andrés; Kalergis Parra, Alexis Mikes; Fournet, Alexandra; Aguirre, Adam; Veas, Francisco
    Abstract Background Andes virus (ANDV), a rodent-borne Hantavirus, is the major etiological agent of Hantavirus cardiopulmonary syndrome (HCPS) in South America, which is mainly characterized by a vascular leakage with high rate of fatal outcomes for infected patients. Currently, neither specific therapy nor vaccines are available against this pathogen. ANDV infects both dendritic and epithelial cells, but in despite that the severity of the disease directly correlates with the viral RNA load, considerable evidence suggests that immune mechanisms rather than direct viral cytopathology are responsible for plasma leakage in HCPS. Here, we assessed the possible effect of soluble factors, induced in viral-activated DCs, on endothelial permeability. Activated immune cells, including DC, secrete gelatinolytic matrix metalloproteases (gMMP-2 and -9) that modulate the vascular permeability for their trafficking. Methods A clinical ANDES isolate was used to infect DC derived from primary PBMC. Maturation and pro-inflammatory phenotypes of ANDES-infected DC were assessed by studying the expression of receptors, cytokines and active gMMP-9, as well as some of their functional status. The ANDES-infected DC supernatants were assessed for their capacity to enhance a monolayer endothelial permeability using primary human vascular endothelial cells (HUVEC). Results Here, we show that in vitro primary DCs infected by a clinical isolate of ANDV shed virus RNA and proteins, suggesting a competent viral replication in these cells. Moreover, this infection induces an enhanced expression of soluble pro-inflammatory factors, including TNF-α and the active gMMP-9, as well as a decreased expression of anti-inflammatory cytokines, such as IL-10 and TGF-β. These viral activated cells are less sensitive to apoptosis. Moreover, supernatants from ANDV-infected DCs were able to indirectly enhance the permeability of a monolayer of primary HUVEC. Conclusions Primary human DCs, that are primarily targeted by hantaviruses can productively be infected by ANDV and subsequently induce direct effects favoring a proinflammatory phenotype of infected DCs. Finally, based on our observations, we hypothesize that soluble factors secreted in ANDV-infected DC supernatants, importantly contribute to the endothelial permeability enhancement that characterize the HCPS.
  • No Thumbnail Available
    Item
    Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
    (2023) Mondaca Contreras, Sebastián Patricio; Walbaum, Benjamín; Corre, Nicole Le; Ferrés Garrido, Marcela Viviana; Valdés, Alejandro; Martínez-Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Macanas Pirard, Patricia; Ross, Patricio; Cisternas, Betzabé; Pérez, Patricia; Cabrera, Olivia; Cerda, Valentina; Ormazábal, Ivana; Barrera Vásquez, Aldo Vincen; Prado, María E.; Venegas, María I.; Palma, Silvia; Broekhuizen, Richard; Kalergis, Alexis; Bueno, Susan M.; Espinoza, Manuel A.; Balcells Marty, María Elvira; Nervi Nattero, Bruno
    Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.